Enanta Pharmaceuticals, Inc.
ENTA
$13.02
$0.221.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.41% | 22.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.41% | 22.70% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -17.41% | 22.70% | |||
| SG&A Expenses | -2.95% | -12.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.93% | -5.69% | |||
| Operating Income | 2.68% | 22.97% | |||
| Income Before Tax | -2.43% | 23.90% | |||
| Income Tax Expenses | 10.34% | 102.22% | |||
| Earnings from Continuing Operations | -2.44% | 19.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.44% | 19.38% | |||
| EBIT | 2.68% | 22.97% | |||
| EBITDA | 3.29% | 24.19% | |||
| EPS Basic | -2.41% | 19.46% | |||
| Normalized Basic EPS | -7.66% | 23.97% | |||
| EPS Diluted | -2.41% | 19.46% | |||
| Normalized Diluted EPS | -7.66% | 23.97% | |||
| Average Basic Shares Outstanding | 0.01% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||